Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending Transfer to an Over-the-Counter Securities Market

  Senesco Announces Delisting of Common Stock from NYSE MKT LLC and Pending
  Transfer to an Over-the-Counter Securities Market

Business Wire

BRIDGEWATER, N.J. -- November 19, 2012

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT)
received verbal notice from NYSE MKT LLC of the exchange’s decision to delist
the Company’s common stock from the NYSE MKT, effective prior to the open of
trading on Wednesday, November 21, 2012. As previously disclosed, the Company
has been in discussions with NYSE MKT LLC regarding the Company’s continued
inability to meet the exchange’s continued listing requirements. On August 22,
2012, the Company received a notice from NYSE Regulation, Inc. on behalf of
NYSE MKT providing notification that NYSE MKT has determined not to grant the
Company an extension of time to cure the non-compliance and that, therefore,
the NYSE MKT intended to file a delisting application with the Securities and
Exchange Commission striking the Company’s common stock from the NYSE MKT. The
Company requested an appeal of the NYSE MKT’s determination and the Company
was granted a hearing with a committee of NYSE MKT in accordance with the
Company’s rights as set forth in Sections 1203 and 1009(d) of the NYSE MKT
Company Guide. The appeal hearing was held on October 24, 2012 and the NYSE
MKT granted the Company an extension through November 5, 2012, which was
subsequently extended through November 12, 2012 due to the effects of
Hurricane Sandy, within which to regain compliance. As of November 12, 2012,
the Company failed to meet the continued listing requirements and was
subsequently notified of the NYSE MKT’s decision to delist the Company’s
common stock. Upon delisting from the NYSE MKT, the Company intends to have
its common stock quoted on an over-the-counter securities market.

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is running a clinical study in multiple
myeloma with its lead therapeutic candidate SNS01-T, which targets B-cell
cancers by selectively inducing apoptosis by modulating eukaryotic translation
initiation factor 5A (eIF5A), which is believed to be an important regulator
of cell growth and cell death. Accelerating apoptosis may have applications in
treating cancer, while delaying apoptosis may have applications in treating
certain inflammatory and ischemic diseases. Senesco has already partnered with
leading-edge companies engaged in agricultural biotechnology and biofuels
development, and is entitled to earn research and development milestones and
royalties if its gene-regulating platform technology is incorporated into its
partners’ products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Actual results could differ materially from such statements expressed
or implied herein as a result of a variety of factors, including, but not
limited to: the Company’s ability to continue as a going concern; the
Company’s ability to recruit patients for its clinical trial; the ability of
the Company to consummate additional financings; the development of the
Company’s gene technology; the approval of the Company’s patent applications;
the successful implementation of the Company’s research and development
programs and collaborations; the success of the Company's license agreements;
the acceptance by the market of the Company’s products; the timing and success
of the Company’s preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future operating
performance, the quotation of the Company’s common stock on an
over-the-counter securities market, as well as other factors expressed from
time to time in the Company’s periodic filings with the Securities and
Exchange Commission (the "SEC"), as well as other factors expressed from time
to time in the Company’s periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read in
conjunction with the Company’s periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the date of
this press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events or
circumstances.

Contact:

Senesco Technologies, Inc.
Joel Brooks
Chief Financial Officer
or
Leslie J. Browne, Ph.D.
President & CEO
or
Heather Branham
908-393-9393
info@senesco.com
 
Press spacebar to pause and continue. Press esc to stop.